We are a world leader in delivering 14C human ADME programs to the pharmaceutical industry. With over 30 years’ experience, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA/MAA submissions.
We can guide you through each part of the ADME program, from radiosynthesis through to clinical reporting, and deliver any or all of these components on your behalf.
Explore our selection of case studies, fact sheets and scientific posters and see how we can help you to save valuable drug development time and reduce investment costs.
ISSX 2016 - Absorption, metabolism and excretion of 14C-gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
ArchiveISSX 2015 - Integrated Human ADME studies: A review of objectives and outcomes of integrated 14C studies ISSX 2015 - An open-label, single dose study designed to assess the metabolism and mass balance recovery for 14C-Eravacycline in healthy male subjects after oral and intravenous dosing
An integrated strategy to determine the absorption, distribution, metabolism, excretion, and the absolute bioavailability of Bevenopran (CB-5945) in healthy male subjects Overcoming the Challenges of Working with 14C API and 14C IMP in Clinical Development AAPS 2013 Integrated 14C Study Designs to provide intravenous Pharmacokinetics and Human Mass Balance and Metabolism Data froma Single Protocal and a Single Regulatory Submission EACPT 2013 ADME Study of 14C-netupitant Administered as an oral 300mg suspension to healthy male subjects ESMO 2012 FDA Metabolite Safety Testing Guidelines: The Mist Clears ASCPT 2010